secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001104659-25-043023
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon cuts dividend 93% to $0.08/yr; Q1 revenue down 7%, adj EPS $1.02
------------------------------------------------------------------------

- Q1 revenue $1.513B, -7% as-reported (-4% ex-FX); GAAP EPS $0.33, non-GAAP adj EPS $1.02.
- Board declared quarterly dividend $0.02/share (vs prior $0.28), payable June 12 to holders of record May 12.
- Women's Health +10% as-reported (+12% ex-FX) helped by Nexplanon; Biosimilars -17%; Established Brands -11%.
- Vtama on track for $150M full-year revenue; affirms 2025 guidance, expects >$900M FCF before one-time costs.
- Net income $87M, Adjusted EBITDA $484M (32% margin); company prioritizes deleveraging to net leverage <4.0x by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925043023/0001104659-25-043023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465925043023/tm2513730d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-043023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer